Quintet Private Bank Europe S.A. Cuts Position in Agilent Technologies, Inc. $A

Key Points

• Quintet Private Bank Europe S.A. has reduced its stake in Agilent Technologies, Inc. by 15.4%, owning 123,158 shares after selling 22,397 shares in the second quarter.
• Agilent reported earnings of $1.37 per share, meeting analysts' expectations, with revenue of $1.74 billion, reflecting a 10.1% year-over-year growth.
• Analysts have mixed ratings on Agilent, with six giving it a "Buy" rating and six a "Hold," and the average target price set at $139.25.

Quintet Private Bank Europe S.A. cut its stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 15.4% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 123,158 shares of the medical research company's stock after selling 22,397 shares during the period. Quintet Private Bank Europe S.A.'s holdings in Agilent Technologies were worth $14,534,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its position in Agilent Technologies by 13.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock worth $4,279,000 after acquiring an additional 4,362 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Agilent Technologies by 8.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock worth $3,606,000 after purchasing an additional 2,371 shares during the last quarter. Alps Advisors Inc. increased its holdings in Agilent Technologies by 29.5% during the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock worth $1,563,000 after purchasing an additional 3,040 shares during the last quarter. D.A. Davidson & CO. increased its holdings in Agilent Technologies by 30.4% during the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock worth $1,108,000 after purchasing an additional 2,207 shares during the last quarter. Finally, LGT Capital Partners LTD. increased its holdings in Agilent Technologies by 7.6% during the 1st quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock worth $89,870,000 after purchasing an additional 54,302 shares during the last quarter.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the company's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the sale, the chief executive officer owned 37,448 shares in the company, valued at approximately $4,397,893.12. This represents a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. JPMorgan Chase & Co. decreased their target price on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a research report on Thursday, May 29th. Evercore ISI decreased their target price on Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating for the company in a research report on Thursday, August 28th. Leerink Partners lifted their target price on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research report on Friday, May 30th. TD Cowen lifted their target price on Agilent Technologies to $150.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th. Finally, UBS Group decreased their target price on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a research report on Thursday, May 29th. Six research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $139.25.

Agilent Technologies Trading Down 2.8%

Shares of Agilent Technologies stock opened at $123.19 on Monday. The business has a fifty day simple moving average of $119.76 and a 200-day simple moving average of $115.79. The firm has a market cap of $34.92 billion, a price-to-earnings ratio of 28.92, a price-to-earnings-growth ratio of 3.83 and a beta of 1.24. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last announced its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.37. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.Agilent Technologies's revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, equities analysts forecast that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.